Sangamo Therapeutics Inc [NASDAQ: SGMO] stock went on an upward path that rose over 2.93% on Wednesday, amounting to a one-week price decrease of less than -1.88%.
Over the last 12 months, SGMO stock dropped by -48.42%. The one-year Sangamo Therapeutics Inc stock forecast points to a potential upside of 87.07. The average equity rating for SGMO stock is currently 1.83, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $129.10 million, with 245.40 million shares outstanding and 237.64 million shares in the current float. Compared to the average trading volume of 5.15M shares, SGMO stock reached a trading volume of 4754137 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Sangamo Therapeutics Inc [SGMO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SGMO shares is $4.10 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SGMO stock is a recommendation set at 1.83. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Truist have made an estimate for Sangamo Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 13, 2024. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on December 10, 2024, representing the official price target for Sangamo Therapeutics Inc stock. Previously, the target price had yet another drop from $6 to $2, while RBC Capital Mkts kept a Sector Perform rating on SGMO stock. On April 28, 2023, analysts decreased their price target for SGMO shares from 5 to 1.50.
The Price to Book ratio for the last quarter was 24.17, with the Price to Cash per share for the same quarter was set at 0.10.
SGMO Stock Performance Analysis:
Sangamo Therapeutics Inc [SGMO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.88. With this latest performance, SGMO shares dropped by -0.74% in over the last four-week period, additionally sinking by -59.53% over the last 6 months – not to mention a drop of -48.42% in the past year of trading.
Insight into Sangamo Therapeutics Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Sangamo Therapeutics Inc [SGMO] shares currently have an operating margin of -128.52% and a Gross Margin at 86.26%. Sangamo Therapeutics Inc’s Net Margin is presently recorded at -126.63%.
Return on Equity for this stock declined to -75.06%, with Return on Assets sitting at -75.06%.
SGMO Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SGMO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sangamo Therapeutics Inc go to 24.16%.
Sangamo Therapeutics Inc [SGMO] Institutonal Ownership Details
There are presently around $22.34%, or 23.00% of SGMO stock, in the hands of institutional investors. The top three institutional holders of SGMO stocks are: WASATCH ADVISORS LP with ownership of 20.09 million shares, which is approximately 9.8509%. ARMISTICE CAPITAL, LLC, holding 14.06 million shares of the stock with an approximate value of $$5.04 million in SGMO stocks shares; and ARMISTICE CAPITAL, LLC, currently with $$4.26 million in SGMO stock with ownership which is approximately 5.8341%.
